PCT, ICT and HRT for Men: A Mechanistic Framework

How anabolic steroids change hormone production, why recovery fails, and how to separate in-cycle support, post-cycle recovery, fertility care and long-term hormone support.

Complete guide structure

• Opening. The separate goals of ICT, PCT, fertility recovery and long-term HRT

• Block I. Endocrine foundations and steroid pathways

• Part I. How the hypothalamus, pituitary, Leydig cells and Sertoli cells coordinate male function

  • GnRH pulses, daylight and sleep timing, sampling variation, LH demand, FSH action, intratesticular testosterone and INSL3

  • Why LH and hCG can produce different testicular signals

• Part II. Every major route from cholesterol to androgens, estrogens, neurosteroids and corticosteroids

  • Mitochondrial cholesterol entry, the Δ5 and Δ4 routes and classical testosterone formation

  • Progesterone through the complete backdoor route to DHT

  • Progesterone routes to allopregnanolone, cortisol and aldosterone

• Part III. How tissues activate, recycle and clear steroid hormones

  • The 5α-reductase network and practical ways to assess reduced-steroid flux

  • DHT, reversible diols, aromatase, estrogen metabolites and prostate intracrinology

  • SHBG, TBG, liver clearance, conjugation and microbial reactivation

  • Reduced-androgen control of estrogen, DHEA oxygenation, progesterone metabolites and the narrower 6-OXO branch

• Block II. Exogenous anabolic-androgenic steroid exposure

• Part IV. Parent drugs, active metabolites and endocrine effects across the major AAS families

  • Names, oral survival, route, ester, depot persistence and the difference between active and analytical metabolites

  • Testosterone, Δ1, 19-nor, DHT-lineage, heterocyclic and designer steroids

  • AR, PR, ER and GR activity, aromatization, anti-aromatase effects, thyroid effects, SHBG and TBG

  • Historical anabolic-to-androgenic numbers beside an evidence-graded recovery comparison

  • Product substitution, concentration errors and uncertain exposure

• Block III. Locating the failed step

• Part V. The hierarchy of suppression from active exposure to measured hormone output

  • Depot and metabolite persistence, estradiol, androgen and progesterone feedback

  • Central suppression, Leydig under-response, Sertoli impairment and metabolic limits

• Part VI. Ten post-AAS patterns that require different decisions

  • Residual exposure, central suppression, primary or compensated Leydig dysfunction and mixed failure

  • Fertility-dominant, thyroid-metabolic, estrogen-prolactin, tissue-signaling and measurement patterns

• Part VII. Building an interpretable assessment before treatment

  • Exposure history, valid sampling, endocrine tests, thyroid and metabolic context and semen analysis

• Part VIII. Defining recovery through output, pituitary demand, fertility and durability

  • LH beside testosterone, INSL3, semen and stable function after temporary support clears

• Block IV. Intervention during exposure, after exposure and during long-term support

• Part IX. ICT during active AAS use

  • The function to preserve, pregnenolone dose logic and reduced-pathway assessment

  • Protection of blood pressure, cardiac structure, blood count, lipids, vessels, liver, kidneys, glucose handling, fertility, prostate, sleep and mental state

  • Food, supplements, prescription drugs and peptide bioregulators arranged by evidence, target and product identity

  • Current liquid hormone and micronutrient formats mapped to the correct protocol branch

• Part X. Estrogen control, temporary pituitary recruitment and final-resort fertility rescue

  • LHCGR stimulation, SERM response, raloxifene for breast tissue, low-dose exemestane and specialist gonadotropin care

• Part XI. Post-clearance recovery selected by suppression phenotype

  • Thyroid-limited, central, Leydig, fertility, reduced-androgen and upstream-steroid branches

  • T3, DHT, pregnenolone, DHEA and progesterone with direct review conditions

• Part XII. Fertility recovery through Leydig, Sertoli and germ-cell function

  • Intratesticular testosterone, Sertoli-cell fuel, zinc status, semen interpretation and the time required for spermatogenesis

• Part XIII. HRT after metabolic readiness, diagnosis and fertility are settled

  • Conditional T3, DHT, precursor and testosterone branches with route-specific monitoring

• Block V. Decision and feedback

• Part XIV. A phenotype-first ICT, PCT and HRT decision system

  • Active exposure, credible clearance, fertility priority, suppression phenotype and one measured treatment test

• Part XV. Six response patterns that identify success, failure, dependence or a wrong target

• Reference material

• Steroidogenesis and enzyme atlases, AAS dossier template, pattern index, intervention index and references